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Writing about advances in a field of medicine normally includes some pride about progress which one was witness 
to or even a participant in. The younger one is, the more enthusiastically every advance is lauded and welcomed. 
This is human nature and nothing to be complained about. However, when anesthesiologists, having worked and 
struggled in the field of pediatric anesthesia for about 40 years, look back to past advances, a more realistic, even 
painful picture comes to mind. There was a price which a considerable number of patients had to pay for progress, 
ruined health or even death. This experience of decades of practice is rarely presented in the literature but should not 
be forgotten when we proudly remember advances in pediatric anesthesia. (Korean J Anesthesiol 2011; 60: 313-322)
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    The review of the literature in regard to recent advances in 
pediatric anesthesia can be very frustrating from a scientific 
point of view.
    The literature as well as the lectures at scientific meetings are 
full of statements that certain techniques, drugs or tools “are 
becoming more popular” in pediatric anesthesia. What do these 
statements mean scientifically? Do the new techniques, drugs 
or tools serve the needs of our pediatric patients, or rather the 
wishes of parents, caretakers or anesthesiologists - or is the so-
called popularity simply based on current fashions?
    A review article like this cannot cover the entire field of 
pediatric anesthesia, which would fill the volume of a textbook, 
but I shall try to differentiate between current popularity 
and scientifically proven advances in important sub-fields of 
pediatric anesthesia. 
Recent Guidelines in Pediatric Cardiopul­
monary Resuscitation (CPR)
    Cardiac arrest algorithms are of particular importance in 
pediatric anaesthesia since they are life saving when cardiac 
arrest occurs in otherwise healthy children during anesthesia 
due to unexpected adverse events. The last ILCOR (International 
Liaison Committee on Resuscitation) universal arrest algorithm 
was published in 2005, covering pediatric CPR as well [1]. 
    Guidelines do not necessarily reflect the most refined 
clinical standards. But there has been an outspoken attempt 
to find a consensus among a group of interested specialists 
- to give advice for a specific procedure, in this case CPR. 
ILCOR has tried to find a consensus after going through a 
scientific evaluation process and has summarized conclusions 314 www.ekja.org
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and recommendations. This evaluation process is aimed at 
establishing more clinical evidence for future guidelines.
    This doesn't mean that older guidelines are dangerous. 
However, more science is involved in the newest guidelines, 
probably making them a better choice. Too many parts of the 
CPR-process have not been thoroughly investigated. Therefore, 
the clinical experience of clinicians practicing CPR is very 
important. 
    A good example of a randomised study that is missing the 
answer we need for the clinical use of CPR was one carried out 
in a randomized, double blind manner as a rescue therapy for 
in-hospital cardiac arrests in children [2]. A tenfold higher dose 
of adrenaline (100 μg/kg) was given to children during CPR 
when the standard dose of 10 μg/kg failed. The authors couldn't 
identify any benefit of the tenfold higher dose, which might be 
worse than the standard dose, and they do not recommend 
such high doses. This finding doesn't offer any help in clinical 
situations where we double, then triple or quadruple the 
standard dose of adrenaline when the heart doesn't respond 
to CPR. Anaesthesiologists with decades of clinical experience 
in CPR know that some children respond to high doses of 
adrenaline, often showing good neurological outcome, if dosing 
is elevated in a stepwise fashion. A similar experience was 
reported by Todres and Goetting [3,4]. An immediate tenfold 
increase in adrenaline when the standard dose of 10 μg/kg fails, 
reflects unwise clinical practice. The reason why higher doses 
of adrenaline are helpful is probably due to inadequate cardiac 
compression or extraordinarily severe acidosis, preventing 
adrenaline from acting. Relying on their vast clinical experience, 
rescuers should use higher doses of adrenaline before quitting 
resuscitation, as it will help in a fair number of cases. 
What is new in the guidelines of 2005?
    A key point in the guidelines appears to be the importance 
of shortening no-flow times of the circulation during cardiac 
arrest by reducing ventilation periods and shortening check 
times for the presence of a pulse or for effects of defibrillation. 
The success of uninterrupted heart compressions by reducing 
ventilation periods without disturbing other vital parameters 
was demonstrated in a recent study using manikins [5]. 
    Interruption of chest compressions during CPR must be 
minimized!!
Main differences from older CPR-models 
    Children over eight years of age are treated like adults. 
ㆍA compression - ventilation ratio of 30 : 2 at all ages except 
newborns should be performed by a single rescuer. 
ㆍIn newborns and infants a 15 : 2 compression/ventilation 
ratio should be used in a 2-rescuer situation. 
ㆍIn children, the lower third of the sternum should be used 
for chest compression since it may generate a higher blood 
pressure than the usual compression of the middle of the 
chest. 
ㆍAfter one defibrillation, CPR should be continued immedia-
tely without rhythm analysis, to prevent longer no-flow 
times. After two minutes of CPR, the next shock should be 
applied. 
ㆍIn a two-rescuer situation, the airway should be secured 
(tracheal tube, LMA, combitube) and ventilation carried 
out at a rate of 8-10/min. Chest compressions (100/min) 
should not be interrupted by ventilation! 
ㆍDespite lack of scientific evidence in human studies, the 
routine use of vasopressors (adrenaline) is recommended. 
ㆍThere is insufficient evidence to use vasopressin alone or in 
combination with adrenaline.
ㆍReversible conditions (hypoxia, hypovolemia) should be 
corrected immediately!
ㆍA 10-fold higher dose of i.v. adrenaline is not recommended 
in routine CPR when a standard dose has failed.
ㆍWhen intra-tracheal application is unavoidable, 10 x the i.v. 
dose should be given.
ㆍAtropine was not associated with any benefit in CPR.
ㆍSodium bicarbonate is not recommended for routine use 
but might be considered for life-threatening hyperkalemia 
or cardiac arrest associated with hyperkalemia or for pre-
existing severe metabolic acidosis or tricyclic antidepressant 
overdose.
ㆍMagnesium should be given only for hypomagnesemia and 
torsades de pointes. 
ㆍIn hypovolemia, isotonic crystalloids? have the same effect 
as albumin.
Recent guidelines in neonatal resuscitation
    Resuscitation Guidelines for term and preterm infants were 
included in the ILCOR guidelines of 2005. Experimental and 
clinical research, which changed different components of 
CPR, were introduced. Concentration on continuous cardiac 
compression with little interruption by ventilation, and pulse 
checks or rhythm analysis after defibrillation, is mandatory, as 
in adult patients. The importance of keeping the babies warm, 
and avoiding suctioning and airway manipulations as a general 
rule in order to minimize injury to the airway and lung, are the 
top points of emphasis? in the new guidelines. The response 
to ventilation should be assessed by the heart rate and oxygen 
supply modified according to gestational age. Rescuers have to 
keep in mind that their actions in the first minutes of the life of a 
neonate are vital for the entire future life of the neonate [6].315 www.ekja.org
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Regional Anesthesia
    Probably the most important general achievement in pediatric 
anesthesia during the last few years, one influencing all areas 
of pediatric anesthesia, was the re-introduction of regional 
techniques in the late 1980s. This was possible due to the 
advent of safe regional anesthetics (bupivacaine) and the better 
understanding of the skeletal anatomy of infants and children, 
leading to a safer dosing [7]. Although bupivacaine remains the 
most commonly used local anesthetic in infants and children, 
and has the longest duration of action, levobupivacaine and 
ropivacaine, according to the literature, provide a reduced risk 
of neurologic and cardiac toxicity [8].
    General anesthesia combined with regional techniques 
expose children of all ages to less intravenous and inhalational 
anesthetics and analgesics, keeping them almost free of nausea, 
vomiting, itching or unnecessary sedation compared to the sole 
use of general anesthesia. Being fully awake and being able to 
drink early after surgery, and having no problems breathing 
even after prolonged surgery, are great advantages and are 
appreciated by children and parents. With the placement 
of epidural catheters, analgesia can be prolonged for days 
postoperatively.
    Peripheral nerve blocks and caudal anesthesia are very safe, 
but great caution is always mandatory to avoid side effects. 
Safety depends greatly on the sufficient training of pediatric 
anesthesiologists. The well trained pediatric anesthesiologist 
tries to avoid risky modes of application of regional anesthetics 
and is always prepared to treat dangerous side effects (overdoses, 
intravenous administration induced seizures, tip displacement 
of epidural catheters, centrally located abscesses).
    Portable ultrasound equipment of high quality has 
considerably added to anatomical knowledge and the safety 
of nerve blocks. Most importantly, the visualization of tips 
of epidural catheters, in particular when advanced into the 
thoracic area, locates epidural catheters with high reliability. 
There is vast clinical evidence that ultrasound guided regional 
anesthesia is as advantageous as in adult practice. However, 
this view is supported only by a small series of investigations in 
pediatric patients. Nevertheless, a long period of training with 
supervision by experienced instructors, in particular when 
placing neuraxial blocks, appears to be indispensable [9]! 
    This was documented in an exemplary way in two important 
studies. The first, a retrospective study with more than 24,000 
patients, had an unacceptably high rate of severe side effects 
including death and paraplegia. The blocks were performed 
by physicians with an unknown extent of experience [10]. 
The second study, which was prospectively performed by 
experienced pediatric anesthesiologists, showed only minor 
side effects in a similar number of patients [11]. The message 
of these two studies makes it very clear that un-experienced 
anesthesiologists should avoid placing neuraxial blocks!
    Compared to effects in older children, the duration of local 
anesthetics is considerably shorter in infants. [[In spinal 
anesthesia in ex-prematures, an important way to avoid post-
operative apnea is to recall that MEANING IS UNCLEAR]] 
the duration of bupivacaine lasts only about one hour, which 
makes it mandatory to have the operation performed by very 
experienced surgeons who are able to finish the intervention 
during this time window. 
    The introduction of electrical epidural stimulation for 
confirmation and segmental localization of epidural catheters, 
combined with ultrasound guidance for assessing the site of 
needle puncture and catheter advancement from the caudal to 
the thoracic area, seems to add extra safety to epidural catheter 
placement [12]. 
    A very recent paper reviewed an increasing amount of 
literature about ultrasound-guided techniques for neuraxial 
blocks in children [13]. Ultrasound imaging seems to reliably 
predict the anatomical depth of loss of resistance. This is an 
important aid to safely placing epidural catheters, but the 
putative overall advantage of ultrasound guided placement 
of epidural catheters needs to be supported by larger studies 
(although documented outcomes already suggest that there are 
benefits). 
    To quantify side effects of drugs that are ancillary to neuraxial 
blocks - drugs such as clonidine, dexmedetomidine, ketamine 
and opioids - larger epidemiological studies are needed to avoid 
the re-introduction of unnecessary side effects like sedation, 
itching and vomiting.
Inhalational Anesthesia
    Halothane was introduced into clinical practice in 1956 as 
the first non-inflammable anesthetic. Shortly before isoflurane 
and enflurane appeared on the market in 1966, Edmond I Eger 
had developed a stimulus-response test for assessing anesthetic 
potency of the different agents, namely Minimum Alveolar 
Concentration, MAC [14]. It is still the best test to compare 
inhalational anesthetics today [15], and is well known in the 
community of anesthesiologists. 
    Since sevoflurane was released on the Japanese market in 
1992 and approved by the US Food and Drug Administration 
(FDA) in 1995, it has become the induction agent of choice in 
most countries in the world that can afford the higher price 
compared to the extremely cheap halothane. 
    Sevoflurane is considered to be an improvement in 
inhalational anesthesia according to all modern textbooks of 
anesthesia. The most striking advantage of sevoflurane is the 
ease of induction of anesthesia and the rather short recovery 316 www.ekja.org
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times. The side effects, however, are manifold and alarming. 
It is often difficult to rapidly reach a deep level of anesthesia 
with sevoflurane as the sole agent [16]. It can cause conduction 
abnormalities and should be used with great caution in children 
with severe ventricular outflow obstruction [17,18]. 
    Its supposedly far better cardiovascular stability in com-
parison with halothane is described in countless articles and 
comprehensively in all textbooks of pediatric anesthesia. 
However, it is more than astounding that the supposedly most 
important advantage of sevoflurane, cardiovascular stability in 
comparison with halothane, is not supported by the literature 
[19-24]. Authors of important studies, apparently comparing 
vaporizer dials instead of MAC values, addressed this problem 
in an editorial [25], but they did not respond to the questions 
raised. 
    Comparing dialed vol% with calculated MAC values in some 
frequently quoted studies in which volume percent of the 
inhalational agents were documented, show the discrepancy of 
effective doses applied (Table 1). 
    Only a few studies such as Nakae's compared equipotent 
MAC values and found no difference in cardiovascular function 
between the two inhalational agents [21]. Numerous studies 
have apparently compared the maximum output of vaporizers 
of the respective anesthetic agents for induction instead of MAC 
equivalents (Table 2) [26].
    The perioperative cardiac arrest registry showed a decrease 
in arrests from 1994 to 1997 compared to 1998-2004 [27]. 
Arrests due to medication had decreased from 37% to 18%. It 
was speculated that the lower incidence of medication related 
arrests were due to less frequent use of halothane; but no 
evidence was given for this assertion. However, the explanation 
for this decrease might not be related to the better safety profile 
of sevoflurane but to the vaporizer, not permitting such high 
MAC multiples as for halothane, and indicating that halothane 
was regularly overdosed, as documented in references 19, 20, 
and 22-24.
    The scientific approach to comparing halothane and 
sevoflurane becomes even more complicated when nitrous 
oxide is added. Nitrous oxide reduces the MAC of halothane 
by 70% but reduces it only by 20% for sevoflurane [28]. This 
makes the most frequently quoted echo-cardiographic study, 
supposedly demonstrating less hemodynamic depression in 
sevoflurane compared with halothane at 1.5 MAC, irrelevant. 
[[Due to the addition of nitrous oxide 2.1 MAC halothane with 
1.7 MAC sevoflurane were compared and not 1.5 MAC of both 
agents [30]. MEANING IS UNCLEAR.]].
    The high rate of cardiac arrhythmias during halothane 
anesthesia compared to sevoflurane was observed early and 
addressed in many studies. Arrhythmias under halothane have 
been known for many years and are considered in clinical 
practice as an early sign of overdosing. Again, with the addition 
of nitrous oxide to 5 vol% halothane and 8 vol% sevoflurane, an 
unbelievably high rate of arrhythmias under halothane - 62% 
- was recorded in one of the most frequently quoted articles 
comparing both agents [29]. This is an overdose of halothane by 
about 100%, an even that is not encountered in regular clinical 
practice. In clinical practice it is evident that sevoflurane is less 
arrhythmogenic than halothane and thus preferable in patients 
with arrhythmias, but this cannot be proven by such vague 
studies.
    Considering the many studies mentioned above, which were 
not able to demonstrate convincing hemodynamic advantages 
of sevoflurane compared to halothane, a key question has to be 
raised despite the high popularity of sevoflurane: why have we, 
the majority of the community of pediatric anesthesiologists, 
accepted the results of these inadequate, although peer 
reviewed studies? Were the peers reviewing for the journals 
and accepting these studies for publication, not familiar with 
the well known system of MAC? Is there an unidentified bias 
that is operative in too many pediatric anesthesiologists, that 
Table 1.  Doses of Halothane and Sevoflurane in Vol% and MAC of Studies Comparing  Cardiovascular Side Effects of Both Agents
Halothane vol% MAC Sevofl. vol%  MAC % Overdose
Piat
Epstein
Nakae
Sarner
Lerman
Sigston
1994
1995
1995
1995
1996
1997
3.5
5.0
1.6
4.5
4.3
5.0
(3.9)
(5.6)
(1.7)
(5.0)
(4.8)
(5.6)
7.0 
7.0
4.5
7.0
7.0
8.0
(2.8)
(2.8)
(1.8)
(2.8)
(2.8)
(3.2)
43%
100%
0.6%
78%
71%
75%
MAC values according to Coté et al. [29]. Halothane 0.9 vol, sevoflurane 2.5 vol%. Vaporizer dials are shown in vol% according to published 
articles. 
Table 2.  Output of Halothane-vaporizers and Compared to Sevo-
flurane-vaporizers
Agent 
Max. vaporizer  
output
Max. possible MAC 
multiples
Halothane
Sevoflurane 
5 vol%
8 vol%
5.75
2.42317 www.ekja.org
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doesn't permit them to see these striking overdoses? There was 
no reaction from authors or journals when these errors were 
published in 1999.
    This development shows that we, the pediatric anesthesio-
logists, have to take the utmost caution when new drugs for 
children are released on the market. Or - I hesitate to say it - do 
scientific journals need more experienced peer reviewers for 
subspecialties?
    Other serious side effects of sevoflurane, seizures and muscle 
stiffness, and sometimes impeding intubation, have not, to 
date, been investigated thoroughly, although the problem is 
well documented in the literature. 
    A high incidence of seizures (> 6%) was reported in Japan in 
1992 when 8 vol% of sevoflurane was used for mask induction 
without premedication with anticonvulsants [31]. Lowering the 
concentration of sevoflurane to 6 vol% for induction reduced 
the incidence of seizures considerably. For this reason, many 
anesthesiologists don't use doses higher than 6 vol%.
    Since 1999, convincing studies have been presented, showing 
that sevoflurane causes real seizures and not just seizure-
like movements [32]. On positron emission tomography, 
ictally increased regional blood flow during epileptiform EEG 
discharges as well as interictally decreased blood flow were 
documented as real seizures in healthy volunteers receiving 
sevoflurane [33]. Regarding pediatric patients, seizures in 
association with moderate hyperventilation was observed 
in a very high percentage of patients receiving sevoflurane 
[34]. These findings increased awareness of this important 
problem in pediatric anesthesia. Also, parents continued to 
complain about temporary personality changes in children 
taking sevoflurane. These findings were supported by a more 
recent study showing that sevoflurane consistently elicits 
dose-dependent epileptiform discharges at surgical levels of 
anesthesia [35].
    In 2005 a French group cautioned against the use of high 
doses of this agent in pediatric patients [36] and gave some 
practical recommendations to protect against the epileptogenic 
activity of sevoflurane: avoiding hypocapnia particularly in 
infants, using premedication with diazepines (e. g. midazolam), 
adding nitrous oxide for a protective effect, and supplementing 
sevoflurane with narcotics in order to reduce the concentration 
of sevoflurane during anesthesia, thus reducing epileptiform 
activity. 
    [[The quantification of epileptiform encephalographic activity 
may further minimize the occurrence of non-convulsive 
seizures [37]. LOGIC/MEANING IS UNCLEAR.]].
    Two questions remain: (1) how can we best sedate the 
“howling cortex” [38]; (2) could seizure activity elicited by 
sevoflurane kindle epilepsy-like, febrile, infection-related 
seizures?
    The answer to the first question is: today there is greater 
awareness of seizure activity due to the use of sevoflurane, and 
it can be reduced or prevented [36-38]. Reduction/prevention 
methods should be practiced.
    However, it is presently impossible to answer the second 
question since large epidemiological studies are needed to 
support such an assumption. 
    Sevoflurane was thought to have little effect on liver 
function because its biochemical degradation did not lead 
to trifluoroacetyl proteins. However, as early as 1992, hepatic 
injury after sevoflurane was documented [39]. In long-term 
inhalational anesthesia comparing halothane with sevoflurane, 
only the sevoflurane group showed a transient significant 
increase in GSTA, making it a poorer choice for inhalation 
anesthesia in patients with mild liver dysfunction than 
halothane [40]. A safer course, given these findings is to avoid 
all inhalational agents (except nitrous oxide) in all patients 
with even minor impairment of liver function. Reports of 
liver necrosis after sevoflurane continue to be published [41]. 
Speculations about the pathophysiology of liver cell damage 
point at compound A as the culprit.
    Sevoflurane is well established in clinical practice. All side 
effects are accepted by the vast majority of anesthesiologists 
because of the advantages of a more pleasant induction and 
an earlier emergence from anesthesia, as stormy as it might be. 
Why continue to argue about the above mentioned side effects? 
    The first reason is to refresh our awareness of these side 
effects, which apparently have been forgotten by many 
anesthesiologists, in particular the younger generation. 
    The second reason is that a fair number of countries cannot 
afford the use of sevoflurane on a daily basis because of its costs 
[42]. Does that mean that anesthesiologists in these poorer 
countries are practicing anesthesia of lower quality or even with 
less safety when using halothane?
    By no means! These colleagues should not be discouraged! 
Halothane has a good safety record over more than 50 years, 
provided that overdosing is prevented and well known 
contraindications are avoided. It takes a few extra minutes for 
induction of anesthesia and emergence from anesthesia - with 
far less severe emergence agitation compared to sevoflurane 
[43]! If the regular dose of about three MAC (based on studies 
of one year old infants) is used for induction without additives, 
2.7 vol% of halothane is equivalent to 7.5 vol% sevoflurane. 
Adding 60% N2O, 2.1 vol% halothane are equivalent to 6 vol% 
sevoflurane. With these comparable doses, halothane and 
sevoflurane show the same hemodynamic depression in 
otherwise healthy patients. Again, it is more than surprising 
that the well known MAC-equivalences are rarely applied in the 
large body of published literature!
    Scientifically proven advantages of sevoflurane remain the 318 www.ekja.org
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reasons for its use in arrhythmic patients and in those requiring 
subcutaneous adrenaline injections in plastic surgery. Whether 
children with congenital heart defects and cyanosis do profit 
from sevoflurane in comparison with halothane remains 
questionable since the study supporting this opinion [44] used 
up to 4.4 MAC halothane versus 3.2 MAC sevoflurane. 
    All inhalational agents except N2O are contraindicated 
in icteric ictal? Children, whereas N2O is the best choice of 
inhalational analgesia if there is difficulty obtaining i.v. access.
    Inhalational anesthesia in pediatrics needs experienced 
anesthesiologists with a high awareness of the side effects of any 
anaesthetics currently available on the market. More detailed, 
epidemiological investigations are necessary to determine if 
sevoflurane has long term effects on the brain, in particular 
after a series of anesthetics.
    Desflurane is infrequently used in pediatric anesthesia 
despite a very low blood-gas partition of 0.4, causing very short 
emergence times even after long term application. Due to a high 
incidence of restlessness during emergence from anesthesia 
[45] and the difficulty in using it for mask induction, have kept 
many pediatric anesthesiologists from using it. However, airway 
events after desflurane anesthesia can be reduced considerably 
when children are extubated when they are awake [46].
Intravenous Agents
    Remifentanil, the newest opioid marketed since 1996, is 
unique because an ester linkage allows rapid degradation by 
blood and tissue esterases. The very short half-life permits a 
rapid recovery, within 10 minutes, independent of hepatic or 
renal function [47].
    Unlike all other opioids, the duration of action is independent 
of the administered dose and the duration of infusion, keeping 
the context sensitive half-life constant. This makes it an ideal 
agent for neonatal and infant anesthesia. There is no other 
drug than remifentanil with a greater clearance in neonates 
compared to older children [48]. 
    Since remifentanil needs to be administered by continuous 
infusion, every interruption of the infusion or kinking of the 
intravenous line will quickly cause pain and possibly awareness. 
Postoperatively, pain management must be taken care of by 
regional blocks or other pain relieving medication.
    Overdosing in the sense of toxicity is not possible; however, 
high doses cause bradycardia and hypotension, in particular 
when a bolus is given - which should therefore be avoided [49]. 
    Chest rigidity, a typical opioid-related side effect that can 
prevent proper ventilation, is rarely encountered when bolus-
injections are avoided. Several studies using remifentanil for 
intubation of neonates reported never having encountered 
chest wall rigidity when using up to 2 μg/kg [50]. Another 
study found chest wall rigidity in two out of 15 neonates when 
administering 3 μg/kg as a bolus within 60 sec, a rather high 
dose in a short period of time [51]. Chest wall rigidity seems to 
be related to dosing of remifentanil and appears to be a rare 
event. 
    Acute tolerance is suspected to occur during remifentanil 
infusion. In volunteers, analgesia was only one fourth of the 
initial peak level after three hours of continuous infusion [52]. 
This indicates that the dose needs to be increased during 
anesthesia according to the pain reactions of the patient. 
    Remifentanil alone is not sufficient as a sole anesthetic, even 
when given in higher doses, since it has no hypnotic effect. 
Propofol as a sole hypnotic is a good partner for remifentanil 
for short procedures and for diagnostic interventions without 
postoperative pain as after endoscopies. Intubation with 3 μg 
remifentanil and 4 mg propofol provided excellent intubation 
conditions and adequate analgesia. However, spontaneous 
respiration recurred later than with 1 μg remifentanil alone [53]. 
    Propofol, a pure hypnotic agent, was released on the 
European market rather late in 1996 (in 1989 in the USA!) and 
gained immediate and wide spread acceptance in pediatric 
anesthesia because of rapid onset of anesthesia and quick 
emergence from anesthesia. This made it an almost ideal agent 
for short interventions with little or no postoperative pain such 
as that found during/after endoscopies. A great disadvantage 
of propofol for children is frequently appearing intense 
pain when it is injected intravenously, which can be reliably 
prevented only by inhalational induction. Significant drops 
in blood pressure with propofol induction or co-induction 
remain an important clinical problem today [54,55]. Due to its 
“popularity” it was uncritically used in high doses, often for long 
periods in intensive care units despite strict warnings based 
on pharmacokinetic data [56]. The result was the unnecessary, 
deplorable death of dozens of children and adults from 
propofol infusion syndrome (PRIS). Only a small fraction of 
these cases were reported in the literature according to my own 
experience [57]. It was thought that only doses higher than 4 
mg/kg/hr and infusion periods greater than 48 hrs caused this 
lethal side effect, but now there is evidence that far lower doses 
can be followed by PRIS [58,59]. The danger of PRIS is present 
today. These extremely dangerous side effects are practically 
all preventable by avoiding too high doses and by reacting 
immediately to early symptoms [60].
Clonidine and dexmedetomidine 
    Both drugs are alpha-2 agonists that may cause hypotension, 
bradycardia and somnolence in high doses. However, their 
sedative, anxiolytic, analgesic effects and the absence of 
respiratory depression make alpha-2 agonists very helpful 319 www.ekja.org
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drugs in pediatric anesthesia. Alpha-2 agonists, being used as 
analgesics and sedatives, are associated with an opioid sparing 
effect - typical opioid side effects such as respiratory depression, 
pruritus and urinary retention do not occur. For this reason, 
clonidine is frequently used as an adjunct to neuraxial block, 
with advantageous clinical results [61]. Clonidine is an old drug. 
Its analgesic properties have been used in pediatrics since 1977 
[62]. 
    Dexmedetomidine was released on the market in 1999 in 
the USA for adult use. Initial experiences with this drug in 
children, still being used off label, were published in 2002 
[63]. Dexmedetomidine differs from clonidine by a greater 
alpha-2 receptor affinity, which results in shorter sedation 
times after ending an intravenous infusion, a more pronounced 
anti-shivering effect postoperatively, and a higher degree of 
arousability during long term sedation. The most frequent side 
effects are hypotension, bradycardia, nausea and significant 
hypertension when an initial dose is administered too rapidly 
[64]. The elimination half life of dexmedetomidine is about 2 hr, 
while it about 9 hr for clonidine [65,66].
    Differentiating between these two similar drugs in order to 
provide the best clinical effects in any given case, cannot be 
done yet since convincing direct comparisons between the two 
drugs are missing. Dexmedetomidine as a new drug is far more 
intensely marketed than clonidine with arguments derived 
mainly from case reports. We as clinicians are in a conflict, as 
always, when being confronted with promising new drugs that 
are not well investigated in children. We would like to find a 
scientifically based, independent point of view. However, due 
to a lack of data we are prone to make mistakes, and in general, 
we should choose a careful approach to new drugs. This 
classical conflict has been described by well known pediatric 
anesthesiologists, possibly helping us to make appropriate 
decisions and not over-eagerly resort to new drugs [67-69]. 
The well known “old” drugs might have the same if not a better 
safety record. 
    At this point it seems that dexmedetomidine might have some 
advantages in short interventions in day care, and clonidine 
might have some advantages as an additive to regional blocks 
and long term sedation where easy arousability is not needed.
Recently Developed Antagonists 
    Flumazenil, an antagonist used in diazepine overdoses, 
has had an established place in pediatric anesthesia for 
about 20 years. Using it as routine antagonist in midazolam-
supported anesthesia for target controlled anesthesia is rarely 
done anymore with the advent of propofol and remifentanil. 
However, it remains a safe mode of anesthesia. 
    Suggamadex, an antagonist of the long acting muscle relaxant 
rocuronium, is a very helpful new tool (on the market since 
2008) in pediatric anesthesia. It reverses even an immediately 
administered relaxant without permitting a rebound effect. 
A high dose of rocuronium can be used for rapid sequence 
induction and be reversed within about one minute with a dose 
of 4.0 mg/kg. When using 2.0 mg/kg, three minutes are needed 
for reversal [70]. Suggamadex is still very expensive. Therefore, it 
is used only for well founded indications.
Airway Care in Pediatric Anesthesia 
    Dealing with delicate airways in infants and children is a 
very important part of pediatric anesthesia! A large body of 
literature and many presentations at international meetings 
have dealt with this problem. Unfortunately, the discussions 
are presently narrowed to the entirely unscientific slogan: 
“cuffed versus un-cuffed intubation” [71-74]. There is no 
“versus” position between different tubes per se, but an intense 
interest in identifying the least traumatic side effects of different 
brands and designs of tracheal tubes. This question was not 
convincingly answered by the above quoted studies since their 
outcome measure was simply inadequate. Dealing with airway 
injuries of different severity after intubation, it is obvious that 
ulcers, abrasions of the mucosa, and penetrating injuries on 
different anatomical levels (glottic, subglottic, tracheal) do not 
cause stridor as long as the lumen of the airway is not narrowed 
by 50%. These sometimes dangerous injuries are not accessible 
to direct view and need to be evaluated by simple optical 
instruments (Hopkins or Bonfils lenses) in order to prevent 
the development of granulation tissue and later scarring and 
stenoses. Stridor cannot differentiate between benign injuries 
(temporary edema) or injuries needing an immediate surgical 
intervention. Endoscopy is needed for studying the effects of 
tracheal tubes in vivo; otherwise we will lose the most important 
information we need, a detailed description of possible injuries, 
whether they cause stridor or not. 
    In addition, an indispensable prerequisite for comparing 
tracheal tubes in humans was the design of the tubes (same 
outer diameters, cuffs of identical shape and position on the 
shaft). They had to be standardized before comparing tracheal 
tubes, which was not the case in any of the above mentioned 
studies. 
    If damage in a tunnel is suspected, specialists with good light 
sources are sent out to make visible what has happened to the 
walls or floor of the tunnel and to give a report. We need to do 
the same when the airway, a classical tunnel for the passage of 
air, has to be examined for possible damage.
    The inadequacy of outcome measures for assessing airway 
injury was already addressed in 1987. They recommended 
airway endoscopy to initiate preventive treatment, e. g. anterior 320 www.ekja.org
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cricoid split, when airway injury was suspected [75]. In 1997, 
five children with subglottic stenosis due to intubation trauma 
were described. Only one (20%) presented with stridor after 
extubation [76]. In 2005 it was noticed that not a single one 
of the studies designed to compare the incidence of airway 
trauma between children intubated with cuffed or un-cuffed 
tubes addressed subglottic stenosis, the worst side effect of 
airway injury. Since this is the worst complication of intubation, 
appearing late after the trauma, without the symptom of stridor, 
it should be the center of our concerns! This observation shows 
the inadequacy of all studies using stridor only as the only 
outcome measure! There is no rational reason for assuming that 
the absence of immediate post-extubation stridor excludes late 
subglottic stenosis [77]. 
    This observation was supported in 2009 by two studies 
with an unusually large number of endoscopic documents, 
demonstrating that the mechanisms of airway injury were 
due to intubation and late scar development and were not 
accompanied by stridor [78,79]. 
    However, this ample evidence of the insufficiency of stridor 
as an outcome measure has not prevented further publications 
which still do not use the indispensable optical instruments (79). 
Such studies make comparisons between differently designed 
tracheal tubes impossible, and they thus prevent the acquisition 
of convincing results. It is not easy to answer the question why 
so many scientists in pediatric anesthesia are reluctant to use 
simple instruments to detect airway trauma as early as possible, 
in order to prevent late consequences for the patient. Is it a 
general fear of embarking on new technologies? Is it too difficult 
to imagine the value of endoscopic interventions, not having 
been exposed to airway endoscopy previously? 
    It is all the more remarkable that since the beginning of 2010, 
several departments of pediatric anesthesia in ASEAN countries 
have embarked on using airway endoscopy to check for injuries 
on a regular basis. Lectures by external instructors and training 
in the operating rooms were part of this program. Mainly 
Hopkins and Bonfils lenses* were used since handling of these 
rigid instruments is far easier to learn and the quality of pictures 
considerably higher compared to the rather slow flexible fiber-
optic endoscopy. (*Karl Storz GmbH & Co-KG, Tuttlingen, 
Germany). 
    Lectures combined with training in the operating room 
show astounding immediate results. Practically all airway 
complications and injuries reported in the literature could be 
documented within a short time by endoscopy, such as injuries 
due to too large cuffed or uncuffed tubes, mucosal trauma by 
malpositioned cuffs, or folds of uninflated cuffs. Inflammation 
of ulcers or abrasions could be documented as evidence of 
older injuries that could not be detected without endoscopes. 
Unexpected malformations and narrowing of the airway could 
be detected early and expert help for intubation obtained. 
    [[Members of the respective teams thought this experience 
to be enlightening, making them independent of the current 
literature by observing side effects of intubation with their own 
eyes. MEANING IS UNCLEAR.]].
    Thinking about advances in any medical field will always 
show progress accompanied by adverse effects that were not 
known before the advances. Knowing this rule, we have to be 
aware of unknown side effects when new drugs or techniques 
are introduce into clinical practice and we must use the 
novelties with great care.
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